Complement activation by Proteus mirabilis negatively charged lipopolysaccharides

Journal of Endotoxin Research

Volumn 6, Issue 3, 2000, Pages 223-234

  Kaca, Wieslaw ^a,b   Literacka, Elzbieta ^c   Sjoholm, Anders G ^d   Weintraub, Andrej ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; BACTERIUM LIPOPOLYSACCHARIDE; CARBOXYL GROUP; CELL MEMBRANE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; ENDOTOXIN; HEXOSAMINE; O ANTIGEN; URONIC ACID;

ANIMAL CELL; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; CELL WALL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FIXATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; HUMAN; HUMAN TISSUE; IMMUNOELECTROPHORESIS; NONHUMAN; NORMAL HUMAN; PROTEUS MIRABILIS; RHEUMATOID ARTHRITIS; SERUM; SHEEP ERYTHROCYTE; STRAIN DIFFERENCE; URINARY TRACT INFECTION;

ANIMAL; ANTIBODIES, BACTERIAL; BLOOD; CARBOHYDRATE SEQUENCE; COMPARATIVE STUDY; COMPLEMENT 3; COMPLEMENT ACTIVATION; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; LIPOPOLYSACCHARIDES; MOLECULAR SEQUENCE DATA; O ANTIGENS; PROTEUS MIRABILIS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0033774578     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/09680519000060030301     Document Type: Article

References (42)

1. Sturvite stones
2. Potential virulence factors of Proteus bacilli
3. Gram-negative bacteremia in non-neutropenic patients: A 3-year review
4. Bacteremia in the elderly
5. Changing patterns of bacterial nosocomial infections: A nine-year study in a general hospital
6. Antibodies to Klebsiella pneumoniae in Duch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis
7. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls
8. Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis
9. Activation of human serum complement by bacterial lipopolysaccharides: Structural requirements for antibody independent activation of classical and alternative pathways
10. Complement activation via the alternative pathway by purified Salmonella lipopolysaccharides is affected by its structure but not its O-antigen's length
11. Salmonella activated complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen
12. Serological studies of an acid-labile O-polysaccharide of Proteus vulgaris OX19 lipopolysaccharide using human and rabbit antibodies
13. The structure of lipopolysaccharide of Gram-negative bacteria. III. The structure of O-antigens: A review
14. Structure of the O-antigenic polysaccharides of Proteus bacteria
15. The core region of Proteus mirabilis R110/1959 lipopolysaccharide
16. Isolation and structural characterisation of an 8-O-(4-amino-4-deoxy-β-L-arabinosyl)-3-deoxy-D-manno-octulosonic acid disaccharide in the lipopolysaccharide of a Proteus mirabilis deep rough mutant
17. Structural and serological studies of the O-antigen of the bacterium Proteus mirabilis OXK (serogroup O3) used in Weil-Felix test
18. Structural investigation of the lipopolysaccharide from Proteus mirabilis R45 (Re-chemotype)
19. Structures of the O-antigen of Proteus bacilli belonging to OX group (serogroup O1-O3) used in Weil-Felix test
20. The comparison of some biological activities of lipopolysaccharides obtained from smooth and rough Proteus mirabilis strains
21. Bacterial lipopolysaccharides: Extraction with phenol-water and further application of the procedure
22. Effect of time, temperature and anticoagulants on in vivo complement activation: Consequences for collection and preservation of samples to be examined for complement activation
23. Activation of complement by human haemoglobin and by mixture of haemoglobin and bacterial endotoxin
24. Measurements of C3 conversion by ELISA estimation of neo-determinants on the C3d moiety
25. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3
26. Normal human serum of C3q factor D and properdin: Its use in studies of complement activation
27. The Kolomogorov-Smirnov, Cramer-von Mises tests
28. The structure and serological specificity of Proteus mirabilis O43 O antigen
29. Structural and immunochemical studies of two cross-reactive Proteus mirabilis O-antigens, O6 and O23, containing β1-3 linked 2-acetamido-2-deoxy-D-glucopyranose residues
30. Structures of the O-specific polysaccharide of the bacterium Proteus mirabilis O30
31. Structure of the O-specific polysaccharide of the bacterium Proteus mirabilis O10 containing L-altruronic acid, a new component of O-antigens
32. Biochemistry of C3 and related thiolester proteins in infection and inflammation
33. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c
34. Complement processing and immunoglobulin binding to Neisseria gonorrheae in vitro simulates in vivo effects
35. Sensitivity to bactericidal effect of human serum of Proteus strains from clinical specimens
36. Complement C1q activation in degeneration articular cartilage of rheumatoid arthritis patients: Immunohistochemical studies with an active form specific antibody
37. Complement components and their activation products in pleural fluids
38. Antibiotic sensitivity and protiocine typing of Proteus mirabilis strains associated with rheumatoid arthritis
39. Complement activation in septic baboons by neoepitope-specific assays for C3b/iC3b/C3, C5a and the terminal C4b-9 complement complex (TCC)